MX2009004611A - Formulaciones de inhibidores de enzimas de fosfolipasa. - Google Patents

Formulaciones de inhibidores de enzimas de fosfolipasa.

Info

Publication number
MX2009004611A
MX2009004611A MX2009004611A MX2009004611A MX2009004611A MX 2009004611 A MX2009004611 A MX 2009004611A MX 2009004611 A MX2009004611 A MX 2009004611A MX 2009004611 A MX2009004611 A MX 2009004611A MX 2009004611 A MX2009004611 A MX 2009004611A
Authority
MX
Mexico
Prior art keywords
formulations
enzyme inhibitors
phospholipase enzyme
phospholipase
inhibitors
Prior art date
Application number
MX2009004611A
Other languages
English (en)
Inventor
Mannching Sherry Ku
Frances Anne Donahue
Marc Sadler Tesconi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009004611A publication Critical patent/MX2009004611A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Indole Compounds (AREA)

Abstract

La presente invención se refiere a formulaciones de inhibidores de enzimas de fosfolipasa, tal como PLA2 citosólica, composiciones que contienen las misma y procesos para la elaboración de las mismas.
MX2009004611A 2006-10-31 2007-10-30 Formulaciones de inhibidores de enzimas de fosfolipasa. MX2009004611A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85556906P 2006-10-31 2006-10-31
PCT/US2007/082982 WO2008055146A2 (en) 2006-10-31 2007-10-30 Formulations of phospholipase enzyme inhibitors

Publications (1)

Publication Number Publication Date
MX2009004611A true MX2009004611A (es) 2009-05-22

Family

ID=39345045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009004611A MX2009004611A (es) 2006-10-31 2007-10-30 Formulaciones de inhibidores de enzimas de fosfolipasa.

Country Status (13)

Country Link
US (1) US20100056520A1 (es)
EP (1) EP2077834A2 (es)
JP (1) JP2010508357A (es)
CN (1) CN101573111A (es)
AR (1) AR063746A1 (es)
BR (1) BRPI0718030A2 (es)
CA (1) CA2667864A1 (es)
CL (1) CL2007003145A1 (es)
MX (1) MX2009004611A (es)
PE (1) PE20081474A1 (es)
RU (1) RU2009116423A (es)
TW (1) TW200824686A (es)
WO (1) WO2008055146A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2614144B1 (en) 2010-09-08 2015-07-22 Twincore Zentrum für Experimentelle und Klinische Infektionsforschung GmbH Use of inhibitors of phospholipase a2 for the treatment or prevention of flavivirus infection
WO2023012322A1 (en) * 2021-08-05 2023-02-09 Pharvaris Gmbh Lipid-based composition for oral administration of bradykinin b2-receptor antagonists

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
JP4761093B2 (ja) * 1997-12-10 2011-08-31 シクロスポリン セラポイティクス リミテッド オメガ−３脂肪酸油を含む医薬組成物
US6500853B1 (en) * 1998-02-28 2002-12-31 Genetics Institute, Llc Inhibitors of phospholipase enzymes
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
EP1151755B1 (en) * 2000-05-04 2005-03-16 Panacea Biotec Limited Pharmaceutical compositions comprising cyclosporin as active ingredient
ATE437629T1 (de) * 2001-10-19 2009-08-15 Isotechnika Inc Neue cyclosporin-analoge mikroemulsionsvorkonzentrate
KR100973665B1 (ko) * 2001-12-03 2010-08-04 와이어쓰 엘엘씨 세포질 포스포리파제 ａ2의 억제제
EP1340497A1 (en) * 2002-03-01 2003-09-03 Novagali Sas Self emulsifying drug delivery systems for poorly soluble drugs
US20050058670A1 (en) * 2003-09-09 2005-03-17 Jong-Soo Woo Oral itraconazole composition which is not affected by ingested food and process for preparing same
GT200500310A (es) * 2004-11-19 2006-06-19 Compuestos organicos

Also Published As

Publication number Publication date
PE20081474A1 (es) 2008-11-24
CA2667864A1 (en) 2008-05-08
CN101573111A (zh) 2009-11-04
CL2007003145A1 (es) 2008-01-25
AR063746A1 (es) 2009-02-18
RU2009116423A (ru) 2010-12-10
WO2008055146A2 (en) 2008-05-08
WO2008055146A3 (en) 2008-10-09
WO2008055146A9 (en) 2008-08-21
EP2077834A2 (en) 2009-07-15
TW200824686A (en) 2008-06-16
BRPI0718030A2 (pt) 2013-11-12
US20100056520A1 (en) 2010-03-04
JP2010508357A (ja) 2010-03-18

Similar Documents

Publication Publication Date Title
JO2761B1 (en) Derivatives of alcohols 1-phenyl-2-pyridinealkyl as inhibitors
TW200718687A (en) Inhibitors of cytosolic phospholipase A2
MX2010006743A (es) Prevencion enzimatica y control de la biopelicula.
MX2009007999A (es) Hidrolisis de almidon utilizando fitasa con una alfa amilasa.
EA201000149A1 (ru) Производные 1-фенил-2-пиридинилалкиловых спиртов в качестве ингибиторов фосфодиэстераз
WO2007087259A3 (en) Enzyme and photobleach containing compositions
MX2010009456A (es) Composicion detergente que comprende lipasa.
WO2007145964A3 (en) Enzyme stabilizer
MX2009004739A (es) Efectos biologicos mejorados de composiciones que comprenden acido rosmarinico.
WO2008153753A3 (en) Compositions and particles containing cellulosic fibers and stabilized- and/or activated- urease inhibitors, as well as methods of making and using the same
IN2013MN00501A (es)
MX342128B (es) Compuestos farmaceuticos.
MX2009011754A (es) Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
MY162813A (en) Compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same
EP2029762A4 (en) ENZYME COMPOSITIONS FOR ENHANCED ENZYMATIC HYDROLYSIS OF CELLULOSE AND METHODS OF USE THEREOF
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
MX2009011753A (es) Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
IL198979A0 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
EP2029761A4 (en) ENZYME COMPOSITIONS AND METHODS FOR IMPROVED ENZYMATIC HYDROLYSIS OF CELLULOSE
WO2009040314A3 (de) Neue heteroarylsubstituierte acetonderivate, geeignet zur hemmung der phospholipase a2
WO2008019069A3 (en) Enzymatic aqueous acylation
WO2008055148A3 (en) Semi-solid formulations of phospholipase enzyme inhibitors
MX361011B (es) Inhibidores de amida hidrolasa de ácido graso.
MX2009004611A (es) Formulaciones de inhibidores de enzimas de fosfolipasa.
WO2006104751A3 (en) Methods and compositions for modulating rho-mediated gene transcription